Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-CIDP 1: HyQvia in CIDP
NCT02549170Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2015
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
A Phase 3 trial of Human normal immunoglobulin G in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Takeda. Started Dec 2015; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02549170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549170.